Results 51 to 60 of about 1,567 (130)

Antibacterial Discovery and Development: From Gene to Product and Back

BioMed Research International, Volume 2015, Issue 1, 2015., 2015
Concern over the reports of antibiotic‐resistant bacterial infections in hospitals and in the community has been publicized in the media, accompanied by comments on the risk that we may soon run out of antibiotics as a way to control infectious disease.
Victor Fedorenko, Olga Genilloud, Liliya Horbal, Giorgia Letizia Marcone, Flavia Marinelli, Yossi Paitan, Eliora Z. Ron, Metin Guru   +7 more
wiley   +1 more source

Development and Validation of Stability Indicating RP‐HPLC Method for Estimation of Ceftaroline Fosamil in Bulk and Its Parenteral Dosage Forms

International Scholarly Research Notices, Volume 2013, Issue 1, 2013., 2013
The present method describes the development of a validated RP‐HPLC method for determination of ceftaroline fosamil in presence of its degradation products or other pharmaceutical excipients. The drug substance was subjected to stress conditions of acid, alkali, and oxidative and thermal degradation studies. Separation was carried out on a C‐18 X‐terra
A. Suneetha, K. China Venkanna, G. Alberti, G. Erny   +3 more
wiley   +1 more source

Ceftaroline fosamil in the treatment of methicillin-resistant Staphylococcus aureus [PDF]

Ceftaroline fosamil, a cephalosporin approved by the FDA for treating infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Staphylococcus aureus, particularly MRSA strains, poses a significant health risk due to antibiotic resistance.
D., Chandrakala, K., Meghana, P., Sahad, Gowda, Medhini H.   +3 more
core   +1 more source

Discrepancies in Beta‐Lactam Antibiotics Cross‐Reactivity: Implications for Clinical Practice

Allergy, Volume 80, Issue 11, Page 3108-3114, November 2025.
Four studies previously published on beta‐lactam antibiotics cross‐reactivity were compared head‐to‐head. These studies covered 51 antibiotics, theoretically leading to 2550 potential recommendations regarding alternatives in case of specific allergies. The studies analysed different sets of beta‐lactam antibiotics.
Evelien Maria Hutten, Maja Bulatović Ćalasan, Jason Anthony Trubiano, Rick Gert‐Jan Pleijhuis, Ingrid Terreehorst   +4 more
wiley   +1 more source

A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Antibiotics, 2019
Objective: The objective of this review is to describe the outcomes of patients treated with ceftaroline in the non-Food and Drug Administration (FDA) approved indication of methicillin-resistant Staphylococcus aureus (MRSA) infections in both pediatric ...
Nicole Lounsbury, Mary G. Reeber, Georges Mina, Christiane Chbib   +3 more
doaj   +1 more source

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost

Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 378-385, August 2025.
Model‐informed drug development (MIDD) integrates data to quantify benefit/risk informing objective drug discovery and development decisions. An additional critical benefit of MIDD is postulated to be improvement in trial and program efficiencies. While the application of MIDD has grown, there have been no clear examples across programs to demonstrate ...
Vaishali Sahasrabudhe, Timothy Nicholas, Gianluca Nucci, Cynthia J Musante, Brian Corrigan   +4 more
wiley   +1 more source

Ceftaroline Exhibits Promising In Vitro Activity Against Methicillin‐Resistant Staphylococcus aureus Clinical Isolates From Alexandria, Egypt

International Journal of Microbiology, Volume 2025, Issue 1, 2025.
Introduction: Ceftaroline is a fifth‐generation cephalosporin that was recently introduced into the Egyptian market for the treatment of methicillin‐resistant Staphylococcus aureus (MRSA) infections. However, limited data are available regarding the susceptibility of MRSA isolates in Egypt to this antibacterial agent.
Hussien H. Sallam, Asmaa A. Ramadan, Nancy M. Attia, Amira ElBaradei, Sherine M. Shawky, Mohammed A. El-Kholy, Todd R. Callaway   +6 more
wiley   +1 more source

Evaluation of the pharmacokinetics and safety of single and multiple ceftaroline fosamil infusions in healthy Chinese and Western subjects

, 2015
Objectives: Two phase I studies in healthy Chinese (NCT01458743) and Western (NCT01612507) subjects evaluated the pharmacokinetics (PK) and safety of single and multiple ceftaroline fosamil 600 mg infusions administered every 8 or 12 hours (q8h or q12h).
Xu, Peng, Li, Jianguo, Yang, Li, Li, Haiyan, Edeki, Timi, Sunzel, Maria, Wilson, David   +6 more
core   +1 more source

Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

, 2012
Click on the Resource Link to access the article (may not be free).Ceftaroline fosamil is a cephalosporin antibacterial approved by the US Food and Drug Administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections ...
Low, Donald E, Lodise, Thomas P
core   +1 more source

In Vivo Efficacy of Ceftaroline Fosamil in a Methicillin-Resistant Panton-Valentine Leukocidin-Producing Staphylococcus aureus Rabbit Pneumonia Model.

, 2014
International audienceCeftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a cephalosporin with broad-spectrum in vitro activity against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and ...
Croisier-Bertin, Delphine, Dumitrescu, Oana, da Silva, Sonia, Piroth, Lionel, Chavanet, Pascal, Hayez, Davy, Vandenesch, François, Biek, Donald, Lina, Gérard, Charles, Pierre-Emmanuel, Badiou, Cédric, Labrousse, Delphine, Guerard, Pascal   +12 more
core   +1 more source